MBX Biosciences (MBX) Amortizatization of Intangibles (2023 - 2026)
MBX Biosciences (MBX) reported Amortizatization of Intangibles of $579000.0 for Q1 2026, down 56.89% on a YoY basis from $1.3 million in Q1 2025, and up 4.32% sequentially from $555000.0 in Q4 2025.
MBX Biosciences (MBX) Amortizatization of Intangibles (2023 - 2026) Analysis & Trends
MBX Biosciences (MBX) has 4 years of Amortizatization of Intangibles data on file, last reported at $579000.0 in Q1 2026.
- For the quarter ending Q1 2026, Amortizatization of Intangibles fell 56.89% year-over-year to $579000.0; the trailing twelve-month figure through Mar 2026 stood at $2.8 million (down 24.44% YoY), and the FY2025 full-year result was $3.6 million, up 23.33% from the prior year.
- Amortizatization of Intangibles rose to $579000.0 in Q1 2026, from $555000.0 in the prior quarter.
- In the past five years, Amortizatization of Intangibles ranged from a high of $1.4 million in Q4 2024 to a low of $441000.0 in Q2 2024.
- A 4-year average of $771800.0 and a median of $593500.0 in 2023 frame the typical range for Amortizatization of Intangibles.
- Peak annual rise in Amortizatization of Intangibles reached 167.0% in 2025, while the deepest fall reached 60.27% in 2025.
- Tracing MBX's Amortizatization of Intangibles over 4 years: stood at $600000.0 in 2023, then jumped by 132.83% to $1.4 million in 2024, then tumbled by 60.27% to $555000.0 in 2025, then rose by 4.32% to $579000.0 in 2026.
- Business Quant data shows MBX's Amortizatization of Intangibles at $579000.0 in Q1 2026, $555000.0 in Q4 2025, and $734000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 3.22 Mn |
| 10 | MBX Biosciences | 2.85 Bn | 2.85 Bn | - | 579,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 579,000.00 |
| Mar 31, 2026 | 579,000.00 |
| Dec 31, 2025 | 555,000.00 |
| Dec 31, 2025 | 555,000.00 |
| Sep 30, 2025 | 734,000.00 |
| Sep 30, 2025 | 734,000.00 |
| Jun 30, 2025 | 979,000.00 |
| Jun 30, 2025 | 979,000.00 |
| Mar 31, 2025 | 1.34 Mn |
| Mar 31, 2025 | 1.34 Mn |
| Dec 31, 2024 | 1.40 Mn |
| Dec 31, 2024 | 1.40 Mn |
| Sep 30, 2024 | 587,000.00 |
| Sep 30, 2024 | 587,000.00 |
| Jun 30, 2024 | 441,000.00 |
| Jun 30, 2024 | 441,000.00 |
| Mar 31, 2024 | 503,000.00 |
| Mar 31, 2024 | 503,000.00 |
| Dec 31, 2023 | 600,000.00 |
| Dec 31, 2023 | 600,000.00 |